ReviewCancers2021
Hyperthermic Intraperitoneal Chemotherapy: A Critical Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 47 citations in OpenAlex.
- Refining OVCAR-3 xenograft models of peritoneal carcinomatosis in nu/nu mice: Comparative intraperitoneal implantation strategies and the role of basement membrane matrix.Animal models and experimental medicine · 2026Article
- First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Population pharmacokinetics and pharmacodynamics of intraperitoneal aerosolized nanoparticle albumin-bound paclitaxel (nab-PTX) and metabolites.British journal of clinical pharmacology · 2026Article
- LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer.Bioactive materials · 2026Article
- Transforming cisplatin into targeted photothermal chemotherapeutics through the platinum-phosphate coordination within a hyaluronan nanogel.Science advances · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C.British journal of cancer · 2026Article
- Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer.World journal of gastroenterology · 2026Article
- Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents.Frontiers in immunology · 2026Review
- Early postoperative morbidity and short-term outcomes after cytoreductive surgery and HIPEC for peritoneal surface malignancies: initial single-center experience from Palestine.Frontiers in oncology · 2026Article
- Mucinase fromFrontiers in microbiology · 2026Article
- Review
- Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis.NPJ precision oncology · 2025Article
- First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma.medRxiv : the preprint server for health sciences · 2025Article
- The Role of Prophylactic HIPEC in High-Risk Gastric Cancer Patients: Where Do We Stand?Cancers · 2025Review
- Review
- Computational Evaluation of Improved HIPEC Drug Delivery Kinetics via Bevacizumab-Induced Vascular Normalization.Pharmaceutics · 2025Article
- Review
- Efficacy and safety of laparoscopic pancreaticoduodenectomy combined with a modified perioperative intraperitoneal chemotherapy regimen in resectable pancreatic head cancer: a dual-center retrospective cohort study.Frontiers in oncology · 2025Article
- 3D printing injectable microbeads using a composite liposomal ink for local treatment of peritoneal diseases.Drug delivery and translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With increasing awareness amongst physicians and improved radiological imaging techniques, the peritoneal cavity is increasingly recognized as an important metastatic site in various malignancies. Prognosis of these patients is usually poor as traditional treatment including surgical resection or systemic treatment is relatively ineffective. Intraperitoneal delivery of chemotherapeutic agents is thought to be an attractive alternative as this results in high tumor tissue concentrations with limited systemic exposure. The addition of hyperthermia aims to potentiate the anti-tumor effects of chemotherapy, resulting in the concept of heated intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal metastases as it was developed about 3 decades ago. With increasing experience, HIPEC has become a safe and accepted treatment offered in many centers around the world. However, standardization of the technique has been poor and results from clinical trials have been equivocal. As a result, the true value of HIPEC in the treatment of peritoneal metastases remains a matter of debate. The current review aims to provide a critical overview of the theoretical concept and preclinical and clinical study results, to outline areas of persisting uncertainty, and to propose a framework to better define the role of HIPEC in the treatment of peritoneal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.